Rafael (NYSE:RFL) Raised to Hold at Wall Street Zen

Rafael (NYSE:RFL) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Rafael Price Performance

Shares of RFL stock opened at $2.11 on Friday. The stock has a fifty day moving average price of $2.16 and a 200 day moving average price of $1.59. Rafael has a one year low of $1.12 and a one year high of $3.96. The stock has a market cap of $109.72 million, a P/E ratio of -3.10 and a beta of 0.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RFL. Renaissance Technologies LLC grew its holdings in Rafael by 59.1% during the 1st quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after acquiring an additional 33,111 shares during the last quarter. Geode Capital Management LLC increased its position in Rafael by 25.4% in the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock valued at $526,000 after acquiring an additional 90,417 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Rafael by 10.5% in the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after acquiring an additional 133,024 shares during the last quarter. Finally, Cable Car Capital LP acquired a new position in shares of Rafael during the second quarter worth approximately $173,000. Institutional investors and hedge funds own 11.30% of the company’s stock.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.